NCT01651273 - A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Hypercholesterolemia

Interventions

DRUG

BMS-852927

Capsules, Oral, 0.25 mg, Once daily, 28 days

DRUG

BMS-852927

Capsules, Oral, 1.0 mg, Once daily, 28 days

DRUG

BMS-852927

Capsules, Oral, 2.5 mg, Once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, Once daily, 28 days

Trial Locations (8)

Local Institution, Berlin

Local Institution, Neuss

Local Institution, Brampton

Local Institution, Toronto

Local Institution, Pointe-Claire

Local Institution, Québec

Local Institution, Québec

Local Institution, Victoriaville